培门冬酶治疗儿童急性淋巴细胞白血病研究进展

Research progress of pegaspargase in the treatment of children with acute lymphocytic leukemia

培门冬酶(PEG-ASP)是一种对左旋门冬酰胺酶(L-ASP)进行聚乙二醇化学偶联修饰后的新型门冬酰胺酶制剂,为儿童急性淋巴细胞白血病(ALL)联合化疗的一线药物之一。它不但保留着门冬酰胺酶的生物活性,而且相对L-ASP能减少抗体的产生,延长半衰期,减少过敏反应的发生率。本文就PEG-ASP的药代动力学、抗药性、临床应用及安全性等方面的进展作一简要综述。

Pegaspargase （PEG-ASP） is the polyethylene glycol （PEG） conjugation of L-asparaginase, one of the first-line drugs in the treatment of acute lymphocytic leukemia （ALL）for chirdren. Compared with the L-ASP, PEG- ASP reduces antibody formation, extends half-time, decreases the incidence of allergic reactions while maintaining L- ASP＇s activity. In this paper, the progress on the pharmacokinetics, drug resistance, clinical application and safety of PEG-ASP are reviewed.